Company intelligence / Profile preview

Celgene

Summit, New Jersey, United States of Americabms.com ↗

Ownership: Public · BMY
Development stage: Commercial

Overview

Celgene has successfully developed multiple commercial products including Revlimid, Pomalyst, Thalomid, and Abraxane. Revlimid generated $8.2 billion in 2017, Pomalyst generated $1.6 billion, and Otezla generated $1.3 billion in 2017.

Therapeutic areas: OncologyImmunologyDermatologyRheumatology
Modalities: Small moleculesProtein regulation therapiesGene regulation therapies
Industry: Pharma

Drug pipeline

5 assets

lenalidomide

Commercial

Indications: Multiple myeloma

4 more assets in the full pipeline.

Request access →

Partnerships

Rockefeller University

Financials

Market cap: $132.1B
Total revenue: $13B
Enterprise value: $164.2B

Beyond the preview

Go deeper on Celgene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celgene.

Explore the full profile